Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does MECHLORETHAMINE Cause Second primary malignancy? 61 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 61 reports of Second primary malignancy have been filed in association with MECHLORETHAMINE (VALCHLOR). This represents 2.4% of all adverse event reports for MECHLORETHAMINE.

61
Reports of Second primary malignancy with MECHLORETHAMINE
2.4%
of all MECHLORETHAMINE reports
32
Deaths
2
Hospitalizations

How Dangerous Is Second primary malignancy From MECHLORETHAMINE?

Of the 61 reports, 32 (52.5%) resulted in death, 2 (3.3%) required hospitalization.

Is Second primary malignancy Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for MECHLORETHAMINE. However, 61 reports have been filed with the FAERS database.

What Other Side Effects Does MECHLORETHAMINE Cause?

Pruritus (317) Application site pruritus (227) Application site erythema (222) Application site pain (217) Erythema (210) Off label use (207) Condition aggravated (197) Skin discolouration (147) Rash (130) Skin irritation (114)

What Other Drugs Cause Second primary malignancy?

CYCLOPHOSPHAMIDE (1,247) DOXORUBICIN (1,151) VINCRISTINE (908) IMATINIB (763) PALBOCICLIB (658) RITUXIMAB (646) RUXOLITINIB (611) ETOPOSIDE (573) PREDNISONE (517) OCTREOTIDE (496)

Which MECHLORETHAMINE Alternatives Have Lower Second primary malignancy Risk?

MECHLORETHAMINE vs MECLIZINE MECHLORETHAMINE vs MEDROL MECHLORETHAMINE vs MEDROXYPROGESTERONE MECHLORETHAMINE vs MEDROXYPROGESTERONE\MEDROXYPROGESTERONE MECHLORETHAMINE vs MEFENAMIC ACID

Related Pages

MECHLORETHAMINE Full Profile All Second primary malignancy Reports All Drugs Causing Second primary malignancy MECHLORETHAMINE Demographics